Jennifer Cormier
ClearMotion (United States)(US)
Publications by Year
Research Areas
Muscle Physiology and Disorders, Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments, Musculoskeletal pain and rehabilitation, Osteoarthritis Treatment and Mechanisms
Most-Cited Works
- → Comparative Effects of Mirtazapine and Fluoxetine on Sleep Physiology Measures in Patients With Major Depression and Insomnia(2003)164 cited
- → Central Sensitization and Neuropathic Features of Ongoing Pain in a Rat Model of Advanced Osteoarthritis(2015)96 cited
- → Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study(2019)34 cited
- → Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men(2020)15 cited
- → PGN-EDO51, an Enhanced Delivery Oligonucleotide (EDO) for the Treatment of Duchenne Muscular Dystrophy (DMD): Results of a Phase 1 Study in Healthy Volunteers (P3-8.004)(2023)6 cited
- → Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.008)(2018)4 cited
- → Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.006)(2018)3 cited
- → Positive results from a first-in-human study supporting continued development of PGN-EDO51 for the treatment of duchenne muscular dystrophy (DMD)(2023)1 cited
- → SAT-LB073 SJX-653, a Novel Selective NK3 Antagonist, Demonstrates Activity on Pharmacodynamic Markers of NK3 Target Engagement(2019)
- → PHocus: a global Phase 2 study of inhaled mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD)(2025)